Fatigue, Depression, and Obesity in Patients with Rheumatoid Arthritis; More Questions than Answers: Comment on the Article by Katz et al
V. Giannouli
DOI: https://doi.org/10.1002/acr.23020
2017-03-01
Arthritis Care & Research
Abstract:ciation of antibodies to interferon-inducible protein-16 with markers of more severe disease in primary Sj€ ogren’s syndrome. Arthritis Care Res (Hoboken) 2016;68:254–60. 2. Alunno A, Caneparo V, Carubbi F, Bistoni O, Caterbi S, Bartoloni E, et al. Interferon g-inducible protein 16 in primary Sj€ ogren’s syndrome: a novel player in disease pathogenesis? Arthritis Res Ther 2015;17:208. 3. Baldini C, Pepe P, Quartuccio L, Priori R, Bartoloni E, Alunno A, et al. Primary Sj€ ogren’s syndrome as a multiorgan disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford) 2014;53:839–44. 4. Carubbi F, Alunno A, Cipriani P, Bartoloni E, Baldini C, Quartuccio L, et al. A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sj€ ogren’s syndrome. Lupus 2015;24:315–20. 5. Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sj€ ogren’s syndrome. Ann Rheum Dis 2011;70:1363–8. 6. Quartuccio L, Baldini C, Bartoloni E, Priori R, Carubbi F, Corazza L, et al. Anti-SSA/SSB negative Sj€ ogren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev 2015;14:1019–22. 7. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al, and the EULAR Sj€ ogren’s Task Force. Sj€ ogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sj€ ogren’s syndrome. Ann Rheum Dis 2010;69:1103–9. 8. Caneparo V, Cena T, de Andrea M, Dell’oste V, Stratta P, Quaglia M, et al. Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Lupus 2013;22:607–13. 9. Costa S, Mondini M, Caneparo V, Afeltra A, Airo P, Bellisai F, et al. Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis. Rheumatology (Oxford) 2011;50:674–81. 10. Alunno A, Caneparo V, Bistoni O, Caterbi S, Terenzi R, Gariglio M, et al. The circulating interferon-inducible protein IFI16 correlates with clinical and serologic features in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68: 440–5.